Roche’s Tecentriq scoops up a big win in small cell lung cancer, grabbing the lead in frontline cases
Roche’s Genentech has scored a landmark success in treating small cell lung cancer, reporting that its PD-L1 checkpoint Tecentriq plus chemo helped patients live longer …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
